GlaxoSmithKline Discontinues Flovent Rotadisk
This article was originally published in The Pink Sheet Daily
Executive Summary
The company cites manufacturing issues and low sales in deciding to discontinue the fluticasone dosage form. The asthma product will continue to be available as inhalation aerosol.
You may also be interested in...
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
Pink Sheet Podcast: EUA’s Impact On US FDA, March-In Rights, CBER And Real-Time Oncology Review
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.
Biden’s Moves On AstraZeneca Stockpile Underscore Power Of Vaccine Diplomacy
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.